Mechanistically, this phenomenon is due to the promotion of cancer cell motility through EMT‐related gene reprogramming.29 Moreover, Sun et al revealed that PRAME might be a biomarker candidate for breast cancer.30 Controversially, another report revealed that PRAME inhibits the proliferation and metastasis of breast cancer cells, demonstrating that PRAME might be a tumour suppressor in breast cancer.31 Thus, due to the limited research on the functions of PRAME in breast cancer, it is necessary to further determine the role of PRAME in the development and progression of mammary malignancy. This evidence concerns the gene PRAME and breast carcinoma.